CHENGDU,
China, Nov. 22, 2024 /PRNewswire/ -- On
November 19, Qilianshan
Pharmaceutical Co., Ltd. (Qilian Pharma), a subsidiary of BGM Group
Ltd, welcomed a team of experts from Guilin Pharmaceutical Co.,
Ltd. (Guilin Pharma), including Quality Assurance Engineer Ms. Shen
and Technical Manager Ms. An. The purpose of their visit was to
conduct an on-site audit to pave the way for future cooperation
between the two companies.
Guilin Pharma, a member company of Fosun Pharma, is a
comprehensive pharmaceutical enterprise specializing in the
research, development, production, and sales of chemical drugs.
With a product portfolio that includes tablets, capsules,
injections, and active pharmaceutical ingredients across four major
categories and over 200 varieties, Guilin Pharma stands as the
leading pharmaceutical exporter in Guangxi Province, China.
Throughout the visit, Mr. Lu, the Executive Deputy General
Manager of Qilian Pharma, along with other management personnel,
accompanied the audit team. They provided a comprehensive overview
of the company's innovative production processes, product features,
quality, and market competitive advantages. The audit team
conducted an in-depth review of key areas, including the production
workshop, raw material warehouse, and quality testing center. They
commended Qilian Pharma for the rigor of its production processes,
the advancement of its equipment and facilities, their maintenance
status, and the cleanliness and efficient management of the
production environment.
Both parties collaboratively identified and optimized potential
improvement points in the production process, setting clear
direction and goals for further enhancing product quality and
customer service levels. This effort aims to increase customer
satisfaction and loyalty.
BGM Group is committed to producing safe, effective, and
affordable pharmaceutical ingredients to elevate global healthcare
standards. We will continue to provide our customers with
high-quality products and services.
About BGM Group Ltd
BGM Group Ltd, headquartered in Chengdu, China, is an innovative company
dedicated to the fields of biopharmaceuticals, bio-extraction, and
medical health. Our current product range includes oxytetracycline
APIs, licorice preparations, and crude heparin sodium. The
oxytetracycline API not only provides raw materials for
pharmaceutical companies to produce human antibiotics but also
supports the global breeding and livestock industries to ensure the
safety of poultry and seafood. The crude heparin sodium, after
processing by downstream companies, is transformed into refined
heparin sodium and heparin sodium injection solutions, which are
major anticoagulants. Licorice preparations, such as compound
licorice lozenges, are used as cough suppressants and supplied to
retail pharmacies. For more information, visit the Company's
website at: https://www.bgmgroupltd.com/
Safe Harbor Statement
This news release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "will", "expects", "anticipates",
"future", "intends", "plans", "believes", "estimates", "target",
"going forward", "outlook" and similar statements. Such statements
are based upon management's current expectations and current market
and operating conditions and relate to events that involve known or
unknown risks, uncertainties and other factors, all of which are
difficult to predict and many of which are beyond the Company's
control, which may cause the Company's actual results, performance
or achievements to differ materially from those in the
forward-looking statements. Further information regarding these and
other risks, uncertainties or factors is included in the Company's
filings with the U.S. Securities and Exchange Commission. The
Company does not undertake any obligation to update any
forward-looking statement as a result of new information, future
events or otherwise, except as required under law.
For investor and media inquiries, please contact:
info@qiliancorp.com
View original
content:https://www.prnewswire.com/news-releases/bgm-group-welcomes-guilin-pharma-for-on-site-audit-and-partnership-development-302314204.html
SOURCE BGM Group Ltd